- China: Low US Interest Rates Threaten Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- White House Plans to Freeze Spending to Cut Deficit
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
- China: Low US interest rates threaten recovery
- Report: Swiss banks eye tax pledge for foreigners
- Rolls-Royce gets $2B engine orders for Airbus jets
- Zsa Zsa Gabor has $118,321 tax bill
- US Official: Climate agreement will take time
- Survey shows spike in 1st-time homebuyers
- Neb. meatpacker sued over handling of layoffs
- Dominica signs deal to export drinking water
- Hawaii's natural assets are being eaten up
Text Size 
TOKYO - Japan's Takeda Pharmaceutical and U.S. Amylin Pharmaceuticals said on Monday they will co-develop and commercialize drugs to treat obesity, including two Amylin drugs in mid-stage trials.
Takeda, Japan's biggest drugmaker and best known for its diabetes drug Actos, will pay Amylin $75 million in a one-time up-front payment under the exclusive worldwide agreement.
Amylin, maker of the diabetes drug Byetta, could also receive development and sales-based milestones worth more than $1 billion if the compounds in the agreement were successful, the companies said in a statement.
The agreement includes Amylin's pramlintide/metreleptin and davalintide, which are in Phase II studies in the United States.
Takeda will lead development activities beyond Phase II and all development activities outside the United States. It will shoulder 80 percent of U.S. development costs and 100 percent of costs for obtaining approval for products outside the United States.
Takeda will lead product commercialization and pay 100 percent of the costs for product commercialization in and outside the United States, they said.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
- A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
Data is a real-time snapshot *Data is delayed at least 15 minutes